Longterm Follow-up of Subjects With Diabetes 2 Type Treatment With ex Vivo Gene Therapy

This is a multicenter, long term safety and efficacy follow up study for with insulin dependent diabetes 2 type who have been treated with ex vivo gene therapy product in Ukraine Association of Biobank bio-sponsored clinical studies. After completing the parent clinical study (2 years),eligible subjects will be followed for an additional 8 years for total 10 years post-drugproduct infusion. No investigation drug product will be administered in the study

NCT Number	NCT04642911
Lead Sponsor	Ukraine Association of Biobank
Conditions	Diabete Type 2, Mesenchymal Stem Cell
Enrollment	91 participants
Start Date	2020-10-15
Primary Completion	2021-09-01 (estimated)
Study Completion	2030-10-10 (estimated)
Updated on ClinicalTrials.gov	2021-10-15